These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 2998642

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Preliminary assessment of a novel thromboxane A2 receptor-blocking drug, GR32191, in healthy subjects.
    Thomas M, Lumley P.
    Circulation; 1990 Jan; 81(1 Suppl):I53-8; discussion I59-60. PubMed ID: 2136818
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Role of thromboxane A2 in a microcirculation disorder of the rat inner ear.
    Umemura K, Asai Y, Uematsu T, Nakashima M.
    Eur Arch Otorhinolaryngol; 1993 Jan; 250(6):342-4. PubMed ID: 8260145
    [Abstract] [Full Text] [Related]

  • 25. Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2.
    Lefer AM, Smith EF, Araki H, Smith JB, Aharony D, Claremon DA, Magolda RL, Nicolaou KC.
    Proc Natl Acad Sci U S A; 1980 Mar; 77(3):1706-10. PubMed ID: 6929517
    [Abstract] [Full Text] [Related]

  • 26. Overview of physiological and pathophysiological effects of thromboxane A2.
    Ogletree ML.
    Fed Proc; 1987 Jan; 46(1):133-8. PubMed ID: 2948837
    [Abstract] [Full Text] [Related]

  • 27. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors.
    Mais DE, Saussy DL, Chaikhouni A, Kochel PJ, Knapp DR, Hamanaka N, Halushka PV.
    J Pharmacol Exp Ther; 1985 May; 233(2):418-24. PubMed ID: 2987481
    [Abstract] [Full Text] [Related]

  • 28. Heterogeneity of thromboxane A2 (TP-) receptors: evidence from antagonist but not agonist potency measurements.
    Tymkewycz PM, Jones RL, Wilson NH, Marr CG.
    Br J Pharmacol; 1991 Mar; 102(3):607-14. PubMed ID: 1364826
    [Abstract] [Full Text] [Related]

  • 29. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F, Colombo M, Pierucci L, Volpi D, Dho L, Ukmar G, Rosa B, Salvati P.
    Drugs Exp Clin Res; 1993 Mar; 19(6):249-60. PubMed ID: 8013268
    [Abstract] [Full Text] [Related]

  • 30. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
    De Clerck F, Beetens J, Van de Water A, Vercammen E, Janssen PA.
    Thromb Haemost; 1989 Feb 28; 61(1):43-9. PubMed ID: 2526385
    [Abstract] [Full Text] [Related]

  • 31. On the mechanism of the prolonged action in man of GR32191, a thromboxane receptor antagonist.
    Ritter JM, Doktor HS, Benjamin N, Barrow SE, Stewart-Long P.
    Adv Prostaglandin Thromboxane Leukot Res; 1991 Feb 28; 21A():351-4. PubMed ID: 1825568
    [Abstract] [Full Text] [Related]

  • 32. 7-[(1R,2S,3S,5R)-6,6-dimethyl-3-(4- iodobenzenesulfonylamino)bicyclo[3.1.1]hept-2-yl]-5(Z)-heptenoic acid: a novel high-affinity radiolabeled antagonist for platelet thromboxane A2/prostaglandin H2 receptors.
    Naka M, Mais DE, Morinelli TA, Hamanaka N, Oatis JE, Halushka PV.
    J Pharmacol Exp Ther; 1992 Aug 28; 262(2):632-7. PubMed ID: 1386885
    [Abstract] [Full Text] [Related]

  • 33. Thromboxane A2 in cardiovascular and renal disorders: is there a defined role for thromboxane receptor antagonists or thromboxane synthase inhibitors?
    Smith EF.
    Eicosanoids; 1989 Aug 28; 2(4):199-212. PubMed ID: 2534279
    [Abstract] [Full Text] [Related]

  • 34. BM 13.177, a selective blocker of platelet and vessel wall thromboxane receptors, is active in man.
    Gresele P, Deckmyn H, Arnout J, Lemmens J, Janssens W, Vermylen J.
    Lancet; 1984 May 05; 1(8384):991-4. PubMed ID: 6143969
    [Abstract] [Full Text] [Related]

  • 35. Pharmacological characterization of potent, long-acting thromboxane receptor antagonists, SQ 33,261 and SQ 33,552.
    Harris DN, Michel IM, Goldenberg HJ, Hartl KS, Allen GT, Steinbacher TE, Schumacher WA, Han WC, Hall SE, Floyd DM.
    J Pharmacol Exp Ther; 1992 Apr 05; 261(1):131-7. PubMed ID: 1532833
    [Abstract] [Full Text] [Related]

  • 36. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.
    Parise LV, Venton DL, Le Breton GC.
    J Pharmacol Exp Ther; 1984 Jan 05; 228(1):240-4. PubMed ID: 6319669
    [Abstract] [Full Text] [Related]

  • 37. Maximal blockade of TxA2 without compromised PGI2 formation; a superior profile of the TxA2 receptor blocking drug GR32191 over aspirin.
    Lumley P, Keery RJ, Wharton KA, White BP, Watts IS.
    Adv Prostaglandin Thromboxane Leukot Res; 1991 Jan 05; 21B():603-6. PubMed ID: 1825385
    [No Abstract] [Full Text] [Related]

  • 38. Competitive antagonism at thromboxane receptors in human platelets.
    Armstrong RA, Jones RL, Peesapati V, Will SG, Wilson NH.
    Br J Pharmacol; 1985 Mar 05; 84(3):595-607. PubMed ID: 2580580
    [Abstract] [Full Text] [Related]

  • 39. Inhibition by lipoxygenase products of TXA2-like responses of platelets and vascular smooth muscle. 14-Hydroxy from 22:6n-3 is more potent than 12-HETE.
    Croset M, Sala A, Folco G, Lagarde M.
    Biochem Pharmacol; 1988 Apr 01; 37(7):1275-80. PubMed ID: 2965590
    [Abstract] [Full Text] [Related]

  • 40. Aza-substituted omega-side-chain modifications of 7-oxabicyclo[2.2.1]heptane thromboxane A2 receptor antagonists: structure-activity relationships.
    Nakane M, Reid JA, Haslanger MF, Garber DP, Harris DN, Ogletree ML, Greenberg R.
    Adv Prostaglandin Thromboxane Leukot Res; 1985 Apr 01; 15():291-3. PubMed ID: 3004140
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.